Amani Therapeutics

Amani Therapeutics is a biotechnology company focused on developing more efficient and safer drugs, dedicated to providing breakthrough therapies for patients with severe neuropsychiatric disorders. The company’s AM-01 is a fixed-dose combination product containing clozapine and an NCE that is ready to enter Phase III, with global licensing rights authorized by AstraZeneca. Amani believes that AM-01 has the potential to deliver unparalleled efficacy of clozapine for schizophrenia patients while addressing clozapine's most significant safety risk—severe neutropenia—as well as the burdensome blood monitoring required for its use.